Can serum TGF-beta 1 be used to evaluate the response to antiviral therapy of haemophilic patients with HCV-related chronic hepatitis?

International Journal of Immunopathology and Pharmacology

Volumn 21, Issue 4, 2008, Pages 1007-1012

  Tarantino, Giovanni ^a   Coppola, A ^a   Conca, P ^a   Cimino, E ^a   di Minno, G ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Antiviral treatment; Haemophilia; HCV; TGF beta 1

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; ENZYME ANALYSIS; FEMALE; FOLLOW UP; HEMOPHILIA; HEPATITIS C; HUMAN; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TREATMENT DURATION; TREATMENT RESPONSE; TREND STUDY; VALIDATION PROCESS; VIRUS LOAD;

EID: 59849098308     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200802100426     Document Type: Article

References (21)

1. Assy N, Pettigrew N, Lee SS, Chaudhary RK, Johnston J, Minuk GY. Are chronic hepatitis C viral infections more benign in patients with hemophilia? Am J Gastroenterol 2007; 102:1672-6.
2. Posthouwer D, Makris M, Yee TT, Fischer K, van Veen JJ, Griffioen A, van Erpecum KJ, Mauser-Bunschoten EP. Progression to end-stage liver disease in patients with inherited bleeding disorders and hepatitis C: an international, multicenter cohort study. Blood 2007; 109:3667-71.
3. McMahon C, Pilkington R, Shea EO, Kelleher D, Smith OP. Liver biopsy in Irish hepatitis C-infected patients with inherited bleeding disorders. Br J Haematol 2000; 109:354-9.
4. Dawson MA, McCarthy PH, Walsh ME, McLean CA, Thomson K, Roberts S, Street AM. Transjugular liver biopsy is a safe and effective intervention to guide management for patients with a congenital bleeding disorder infected with hepatitis C. Intern Med J 2005; 5:556-9.
5. Yamada M, Fukuda Y, Nakano I, Katano Y, Takamatsu J, Hayakawa T. Serum hyaluronan as a marker of liver fibrosis in hemophiliacs with hepatitis C virus-associated chronic liver disease. Acta Haematol 1998; 99:212-6.
6. Maor Y, Bashari D, Kenet G, Lubetsky A, Luboshitz J, Schapiro JM, Penaranda G, Bar-Meir S, Martinowitz U, Halton P. Non-invasive biomarkers of liver fibrosis in haemophilia patients with hepatitis C: can you avoid liver biopsy? Haemophilia 2006; 12:372-9.
7. Masaki N, Imamura M, Kikuchi Y, Oka S. Usefulness of elastometry in evaluating the extents of liver fibrosis in hemophiliacs coinfected with hepatitis C virus and human immunodeficiency virus. Hepatol Res 2006; 35:135-9.
8. Fraquelli M, Rigamonti C, Casazza G, Conte D, Donato MF, Ronchi G, Colombo M. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 2007; 56:968-73.
9. Taniguchi H, Kato N, Otsuka M, Goto T, Yoshida H, Shiratori Y, Omata M. Hepatitis C virus core protein upregulates transforming growth factor-beta 1 transcription. J Med Virol 2004; 72:52-9.
10. Kanzler S, Baumann M, Schirmacher P, Dries V, Bayer E, Gerken G, Dienes HP, Lohse AW. Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-beta. J Viral Hepat 2001; 8:430-7.
11. Janczewska-Kazek E, Marek B, Kajdaniuk D, Borgiel-Marek H. Effect of interferon alpha and ribavirin treatment on serum levels of transforming growth factor-beta1, vascular endothelial growth factor, and basic fibroblast growth factor in patients with chronic hepatitis C. World J Gastroenterol 2006; 12:961-5.
12. Marek B, Kajdaniuk D, Mazurek U et al. TGF-beta 1 mRNA expression in liver biopsy specimens and TGF-beta 1 serum levels in patients with chronic hepatitis C before and after antiviral therapy. J Clin Pharm Ther 2005; 30:271-7.
13. Ray S, Broor SL, Vaishnav Y, Sarkar C, Girish R, Dar L, Seth, Broor S. Transforming growth factor beta in hepatitis C virus infection: in vivo and in vitro findings. J Gastroenterol Hepatol 2003; 18:393-403.
14. Calabrese F, Valente M, Giacometti C, Pettenazzo E, Benvegnu L, Alberti A, Gatta A, Pontisso P. Parenchymal transforming growth factor beta-1: its type II receptor and Smad signaling pathway correlate with inflammation and fibrosis in chronic liver disease of viral etiology. J Gastroenterol Hepatol 2003; 18:1302-8.
15. Blackard JT, Kang M, St Clair JB, Lin W, Kamegaya Y, Sherman KE, Koziel MJ, Peters MG, Andersen J, Chung RT, Aids Clinical Trials Group A5071 Study Team. Viral factors associated with cytokine expression during HCV/ HIV co-infection. J Interferon Cytokine Res 2007; 27:263-9.
16. Lee SS. Histological response to interferon alpha-based therapies in hepatitis C. Semin Liver Dis 2004; 24:55-60.
17. Hui AY, Friedman SL. Molecular basis of hepatic fibrosis. Expert Rev Mol Med 2003; 5:1-23.
18. Radkowski M, Gallegos-Orozco FJ, Jablonska J, Colby VT, Walewska-Zielecka B, Kubicka J, Wilkinson J, Adair D, Rakela J, Laskus T. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology 2005; 41:106-14.
19. Tarantino G, Sorrentino P, Conca P, Perrella A, Ragucci P, Perrella O. Low daily dosage of interferon for 1 year after HCV-related end-therapy response. A randomized-controlled study. Liver Int 2003; 23: 413-9.
20. Inagaki Y, Nemoto T, Kushida M et al. Interferon alpha down-regulates collagen gene transcription and suppresses experimental hepatic fibrosis in mice. Hepatology 2003; 38:890-9.
21. Alatrakchi N, Graham CS, van der Vliet HJJ, Sherman KE, Exley MA, Koziel MJ. Hepatitis C virus (HCV)-specific CD8+ cells produce transforming growth factor β that can suppress HCV-specific T-cell responses. J Virol 2007; 81:5882-92.